Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
195
百万円（前年同期比の営業利益改善額）Wording
Conditional
How definitive the wording is.Contents of this document
Financial Results Presentation2026年6月期 第2四半期（中間期）6 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales2,534 Millions of yen+15.3%
Operating profit84 Millions of yen
Ordinary income69 Millions of yen
Net income61 Millions of yen
Operating profit margin3.3%、前年同期比は数値記載なし
Full-year earnings forecast
Net Sales
4,997 Millions of yen
Operating profit
166 Millions of yen
Ordinary income
134 Millions of yen
Net income
115 Millions of yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
売上は業績予想どおり進捗、営業利益・経常利益・純利益は計画超過Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year-on-year improvement in operating income¥195 million
Impact of higher revenue¥99 million
原価低減効果¥56 million
Inventory valuation loss-¥13 million
SG&A cost reduction¥53 million
通期営業利益予想の前年実績比改善¥287 million
通期増収効果¥89 million
通期売上総利益率改善¥204 million
通期販管費増加-JPY 6 million
New initiatives
- PHC社向け移動式免疫発光測定装置『パスファースト』改良モデルの新規製造委託契約
- PSSプラットフォームの拡大と試薬・消耗品のリカーリングビジネス推進
Key KPIsA metric the company considers important as a management benchmark.
PSSプラットフォーム累計販売実績3,000台以上（2016年～2025年12月）
核酸抽出試薬出荷数前年同期比69%増
核酸抽出試薬・消耗品売上高Up 60% year on year
試薬・消耗品売上高構成比39.5%（前年同期29.8%）
Operating profit margin3.3%
Medium-term management plan targets
FY26/6売上高
5,001 Millions of yen
FY27/6売上高
5,564 Millions of yen
FY26/6営業利益
224 Millions of yen
FY27/6営業利益
438 Millions of yen
Capital expenditures
37 Millions of yen
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | 2026年6月期 第2四半期（中間期） |
| Net Sales | 2,534 Millions of yen (YoY +15.3%) |
| Operating profit | 84 Millions of yen |
| Ordinary income | 69 Millions of yen |
| Net income | 61 Millions of yen |
| Operating profit margin | 3.3%、前年同期比は数値記載なし |
| Full-year earnings forecast | Net Sales 4,997 Millions of yen / Operating profit 166 Millions of yen / Ordinary income 134 Millions of yen / Net income 115 Millions of yen |
| Self-assessment against the plan | 売上は業績予想どおり進捗、営業利益・経常利益・純利益は計画超過 |
| Breakdown of Factors Affecting the Change | Year-on-year improvement in operating income ¥195 million / Impact of higher revenue ¥99 million / 原価低減効果 ¥56 million / Inventory valuation loss -¥13 million / SG&A cost reduction ¥53 million / 通期営業利益予想の前年実績比改善 ¥287 million / 通期増収効果 ¥89 million / 通期売上総利益率改善 ¥204 million / 通期販管費増加 -JPY 6 million |
| Key KPIs | PSSプラットフォーム累計販売実績 3,000台以上（2016年～2025年12月） / 核酸抽出試薬出荷数 前年同期比69%増 / 核酸抽出試薬・消耗品売上高 Up 60% year on year / 試薬・消耗品売上高構成比 39.5%（前年同期29.8%） / Operating profit margin 3.3% |
| Medium-term management plan targets | FY26/6売上高 5,001 Millions of yen / FY27/6売上高 5,564 Millions of yen / FY26/6営業利益 224 Millions of yen / FY27/6営業利益 438 Millions of yen |
| Capital expenditures | 37 Millions of yen |
| New initiatives | PHC社向け移動式免疫発光測定装置『パスファースト』改良モデルの新規製造委託契約, PSSプラットフォームの拡大と試薬・消耗品のリカーリングビジネス推進 |
Items this document does not state (17)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.試薬・消耗品の需要増加による増収、製造工程の改善・量産効果による原価低減、組織再編や販管部門の製販区分見直しによる費用抑制を挙げている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.